| Literature DB >> 30851740 |
Sean Coeckelenbergh1,2, Amélie Delaporte3,4, Djamal Ghoundiwal3,4, Javad Bidgoli3,4, Jean-François Fils3,5, Denis Schmartz3,4, Philippe Van der Linden3,4.
Abstract
BACKGROUND: Goal-directed fluid therapy (GDFT) based on dynamic indicators of fluid responsiveness has been shown to decrease postoperative complications and hospital length of stay (LOS) in patients undergoing major abdominal surgery. The usefulness of this approach still needs to be clarified in low-to-moderate risk abdominal surgery. Both pulse-pressure variation (PPV) and pleth variability index (PVI) can be used to guide GDFT strategies. The objective of this prospective randomized controlled trial was to determine if the use of PVI guided GDFT, when compared to PPV guided GDFT, would lead to similar hospital LOS in patients undergoing low-to-moderate risk surgery. Secondary outcomes included amount of fluid administered and incidence of postoperative complications.Entities:
Keywords: Anesthesia; Anesthesiology; Colloids; Crystalloids; Fluid responsiveness; Goal-directed therapy; Hemodynamics
Mesh:
Substances:
Year: 2019 PMID: 30851740 PMCID: PMC6408844 DOI: 10.1186/s12871-019-0707-9
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Fig. 1Goal-directed fluid therapy protocols. Patients were randomized into either PVI or PPV guided groups. PPV pulse pressure variation, PVI Pleth variability index
Fig. 2Flow chart of enrolment, allocation, and analysis
Baseline characteristics, expressed as % (number), mean (+/−SD), or median [IRQ]
| PVI ( | PPV ( | ||
|---|---|---|---|
| Age (year) | 45 (+/−13) | 50 (+/− 13) | 0.124 |
| Female gender | 92.1 (35) | 94.7 (36) | 0.644 |
| Weight (kg) | 72 (+/−15) | 66 (+/− 15) | 0.096 |
|
| 0.154 | ||
| ASA physical status 1 | 29.0 (11) | 44.7 (17) | |
| ASA physical status 2 | 71.1 (27) | 55.3 (21) | |
|
| |||
| Aspirin | 2.6 (1) | 10.5 (4) | 0.165 |
| Beta-blocker | 13.2 (5) | 10.5 (4) | 0.723 |
| ACEI | 7.9 (3) | 2.6 (1) | 0.304 |
| ARB | 5.3 (2) | 5.3 (2) | 1.00 |
| Calcium channel blocker | 5.3 (2) | 2.6 (1) | 0.556 |
| SSRI | 5.3 (2) | 5.3 (2) | 1.000 |
| Antidepressant other | 15.8 (6) | 7.9 (3) | 0.287 |
| Benzodiazepine | 13.2 (5) | 15.8 (6) | 0.744 |
| Hypertension | 31.6 (12) | 15.8 (6) | 0.105 |
| Diabetes | 5.3 (2) | 2.6 (1) | 0.556 |
| Obstructive pulmonary | 5.3 (2) | 13.2 (5) | 0.234 |
| Previous major surgery | 21.1 (8) | 23.7 (9) | 0.783 |
|
| 0.312 | ||
| Laparoscopy (%) | 65.8 (25) | 76.3 (29) | |
| Laparotomy (%) | 34.2 (13) | 23.7 (9) | |
| Surgery Duration (min) | 130 (+/− 75) | 122 (+/−47) | 0.599 |
| Anesthesia Time (min) | 180 [136–215] | 183 [142–229] | 0.670 |
ASA American Society of Anesthesiology, ACEI angiotensin converting enzyme inhibitor, ARB aldosterone receptor blocker, SSRI selective serotonin reuptake inhibitor
Fig. 3Box-plot comparison of the primary outcome, length of stay (LOS). (*) In order to improve readability, one outlier (LOS = 35 days) is not represented in this figure
Study outcomes, expressed as % (number), mean (+/−SD), or median [IRQ]
| PVI | PPV | ||
|---|---|---|---|
|
| |||
| Total colloid (ml) | 500 [0–750] | 250 [0–500] | 0.275 |
| Total crystalloid (ml) | 500 [350–740] | 550 [450–663] | 0.458 |
| Estimated blood loss (ml) | 100 [50–300] | 100 [50–163] | 0.445 |
| Urine output (ml) | 150 [79–250] | 150 [100–250] | 0.803 |
| Intraoperative phenylephrine | 26.3 (10) | 21.1 (8) | 0.589 |
|
| |||
| LOS PACU (min) | 105 [90–135] | 90 [45–135] | 0.382 |
| PACU PONV | 10.5 (4) | 7.9 (3) | 0.692 |
|
| 0.330 | ||
| 0 | 89 (34) | 92 (35) | |
| 1 | 5.3 (2) | 7.9 (3) | |
| 2 | 5.3 (2) | 0 (0) | |
| Hypotension PACU | 5.3 (2) | 7.9 (3) | 0.644 |
| VAS Day 1 score | 1 [0–2] | 2 [0–2] | 0.925 |
| Ward PONV | 7.9 (3) | 7.9 (3) | 1.000 |
| Fever | 7.9 (3) | 2.6 (1) | 0.304 |
| Post-operative complications | 4 (10.5) | 2 (5.3) | 0.395 |
| Time to first ambulation | 1 [1–2] | 2 [1–2] | 0.231 |
LOS length of stay, PONV postoperative nausea or vomiting, PACU post anesthesia care unit, VAS visual analogue scale